Composition for reducing fat and uric acid as well as preparation method, application and product thereof

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a composition for reducing fat and uric acid as well as a preparation method, application and a product thereof. The composition is prepared from the following raw materials: microcos paniculata, fructus crataegi cuneatae, lotus leaves, pueraria mirifica, lalang grass rhizome and lychee seeds. The preparation method comprises the following steps: performing crushing and slicing treatment on the raw materials, performing auxiliary extraction by combining sophoroester, performing step-by-step enzymolysis by utilizing aminopeptidase, cellulase and acid protease, and then performing filtration, concentration and drying. The composition disclosed by the invention can be applied to preparation of health-care products beneficial to controlling body fat and medicines for reducing body fat or uric acid. Compared with existing products, the composition has the advantages that the preparation process is advanced, the dissolution rate of effective components can be effectively increased, the action mechanism is clear, the raw materials are natural and high in safety, and the composition has remarkable effects in the aspects of reducing fat and uric acid and has important application value and wide market prospects.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a fat-reducing and uric acid-lowering composition, a preparation method thereof, an application thereof and a product thereof. Background Art

[0002] Obesity is not only an outward manifestation of excessive body fat accumulation, but also a key risk factor for metabolic syndromes such as cardiovascular disease, diabetes, and fatty liver disease. At the same time, hyperuricemia, a metabolic disease caused by purine metabolism disorders or uric acid excretion disorders, can easily develop into gout if not effectively controlled over a long period of time, leading to joint pain, deformities, and even kidney damage. Studies have shown that obesity and hyperuricemia are closely linked in their pathogenesis, often influencing each other, forming a vicious cycle that further exacerbates disease progression.

[0003] Currently, a wide variety of products are available on the market for fat loss and uric acid reduction. Western-style fat-reducing medications, such as orlistat, can reduce fat absorption by inhibiting gastrointestinal lipase, but they are often associated with side effects such as gastrointestinal discomfort and malabsorption of fat-soluble vitamins. Uric acid-lowering drugs, such as allopurinol and febuxostat, primarily work by inhibiting xanthine oxidase to reduce uric acid production, or, like benzbromarone, by promoting uric acid excretion. However, these drugs can be associated with adverse reactions such as allergic reactions, liver damage, and urate crystal deposition. Long-term use can also lead to drug resistance, limiting their clinical application.

[0004] In the field of traditional Chinese medicine, research on Chinese herbal compositions for reducing fat and lowering uric acid has achieved certain results. Patent CN102771861B discloses a functional beverage containing ingredients such as kudzu root, mulberry leaf, sophora japonica flower, hawthorn, coix seed, fresh Imperata root, chrysanthemum, yam, selfheal, grass jelly, mint, wolfberry, lotus leaf, and cassia seed, thereby preventing the three highs, obesity, and internal heat. Patent CN110236041A provides a botanical beverage containing ingredients such as coix seed, red bean, fresh Imperata root, kudzu root, dried bitter melon, hemp, jujube seed, Prunus mume seed, rice vinegar, green tea leaf, lotus leaf, purslane, wolfberry, hawthorn, and honey, which is effective in treating hyperlipidemia, high blood viscosity, high uric acid, and high blood sugar.

[0005] However, existing traditional Chinese medicine compositions suffer from complex ingredients and low dissolution rates of active ingredients. Some traditional Chinese medicine formulas are simply formulated, lacking scientific formulation rationale and optimized screening. Traditional methods such as decoction make it difficult to fully extract active ingredients, resulting in unstable product efficacy and difficulty meeting modern clinical and market demands. Therefore, developing a safe and effective composition for reducing fat and uric acid is of great significance. Summary of the Invention

[0006] In view of the above-mentioned deficiencies, the present invention provides a composition for reducing fat and lowering uric acid, and its preparation method, application and product.

[0007] The technical solution of the present invention is: In one aspect, the present invention provides a composition for reducing fat and lowering uric acid, the composition comprising the following raw materials: Buza leaves, southern hawthorn, lotus leaves, Pueraria root, Imperata root and litchi seeds; The preparation method of the composition is as follows: S1. Grind and sieve the Buza leaves and lotus leaves, and then mix them to obtain medicinal material powder 1; S2, remove the core of southern hawthorn, crush and sieve, crush the litchi core into granules, and mix them to obtain medicinal material powder 2; S3, slicing Pueraria lobata and Imperata cylindrica root, mixing them, adding distilled water, stirring evenly, adding sophoroside, soaking, repeating extraction and filtration 3 times, combining the filtrate to obtain the drug extract and the residue 1; S4, combining the medicinal material powder 1 and the medicinal residue 1, adding a buffer solution, adding aminopeptidase and cellulase, performing enzymolysis, inactivating the enzymes, and filtering to obtain an enzymatic hydrolyzate 1 and the medicinal residue 2; S5, combining the medicinal material powder 2 and the medicinal residue 2, adding distilled water, adjusting the pH, adding acidic protease, performing enzymatic hydrolysis, inactivating the enzyme, and filtering to obtain an enzymatic hydrolyzate 2; S6, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S7. Filter the enzymatic extract, concentrate and dry to obtain the composition.

[0008] Specifically, the screening in step S1 is: passing through a sieve of at least 40 meshes.

[0009] Preferably, the sieving in step S1 is: 40 mesh sieve, 50 mesh sieve, 60 mesh sieve, 70 mesh sieve, 80 mesh sieve, 100 mesh sieve, 120 mesh sieve, 140 mesh sieve, 170 mesh sieve or 200 mesh sieve.

[0010] More preferably, the sieving in step S1 is: sieving through a 40-mesh sieve.

[0011] Specifically, the screening in step S2 is: passing through a sieve of at least 50 meshes.

[0012] Preferably, the sieving in step S2 is: 50 mesh sieve, 60 mesh sieve, 70 mesh sieve, 80 mesh sieve, 100 mesh sieve, 120 mesh sieve, 140 mesh sieve, 170 mesh sieve or 200 mesh sieve.

[0013] Preferably, the screening in step S2 is: screening through a 50-mesh sieve.

[0014] Specifically, the amount of the sophoroside added in step S3 is 0.5%-1.0% w / w of the mass of the distilled water in step S3.

[0015] Preferably, the amount of the sophoroside added in step S3 is 0.50%-0.55% w / w, 0.55%-0.60% w / w, 0.60%-0.65% w / w, 0.65%-0.70% w / w, 0.70%-0.75% w / w, 0.75%-0.80% w / w, 0.80%-0.85% w / w, 0.85%-0.90% w / w, 0.90%-0.95% w / w or 0.95%-1.00% w / w of the mass of the distilled water in step S3.

[0016] Further preferably, the amount of the sophoroside added in step S3 is 0.50% w / w, 0.75% w / w or 1.00% w / w of the mass of the distilled water in step S3.

[0017] Still further preferably, the amount of sophoroside added in step S3 is 0.50% w / w of the mass of the distilled water in step S3.

[0018] Specifically, the distilled water described in step S3 is added according to a material-liquid ratio of 1 g: 10-15 mL.

[0019] Preferably, the distilled water in step S3 is added according to a material-liquid ratio of 1 g:10-11 mL, 1 g:11-12 mL, 1 g:12-13 mL, 1 g:13-14 mL or 1 g:14-15 mL.

[0020] Further preferably, the distilled water in step S3 is added according to a material-liquid ratio of 1 g:10 mL or 1 g:15 mL.

[0021] Still more preferably, the distilled water in step S3 is in a material-liquid ratio of 1 g:10 mL.

[0022] Specifically, the soaking in step S1 is for 60-120 minutes.

[0023] Preferably, the soaking in step S1 is soaking for 60-70 min, 70-80 min, 80-90 min, 90-100 min, 100-110 min or 110-120 min.

[0024] More preferably, the soaking in step S3 is for 60 minutes.

[0025] Specifically, the extraction temperature in step S3 is 40-60°C.

[0026] Preferably, the extraction temperature in step S3 is 40-45°C, 45-50°C, 50-55°C or 55-60°C.

[0027] Further preferably, the extraction temperature in step S3 is 50°C.

[0028] Specifically, the extraction time in step S3 is 30-50 min.

[0029] Preferably, the extraction time in step S3 is 30-40 min or 40-50 min.

[0030] Further preferably, the extraction time in step S3 is 40 minutes.

[0031] Specifically, the amount of aminopeptidase added in step S4 is 1.0%-1.5% w / w of the mass of the buffer solution in step S4.

[0032] Preferably, the amount of the aminopeptidase added in step S4 is 1.00%-1.05% w / w, 1.05%-1.10% w / w, 1.10%-1.15% w / w, 1.15%-1.20% w / w, 1.20%-1.25% w / w, 1.25%-1.30% w / w, 1.30%-1.35% w / w, 1.35%-1.40% w / w, 1.40%-1.45% w / w or 1.45%-1.50% w / w of the mass of the buffer described in step S4.

[0033] Further preferably, the amount of aminopeptidase added in step S4 is 1.0% w / w, 1.2% w / w or 1.5% w / w of the mass of the buffer in step S4.

[0034] Still more preferably, the amount of aminopeptidase added in step S4 is 1.2% w / w of the mass of the buffer solution in step S4.

[0035] Preferably, the amount of cellulase added in step S4 is 1.0% w / w of the mass of the buffer solution in step S4.

[0036] Specifically, the buffer solution in step S4 is a phosphate buffer solution.

[0037] Specifically, the pH value of the buffer solution in step S4 is 4.5-6.5.

[0038] Preferably, the pH value of the buffer solution in step S4 is 4.5-5.0, 5.0-5.5, 5.5-6.0 or 6.0-6.5.

[0039] Specifically, the buffer solution in step S4 is added at a material-liquid ratio of 1 g: 8-10 mL.

[0040] Preferably, the buffer solution in step S4 is added at a material-liquid ratio of 1 g: 8-9 mL or 1 g: 9-10 mL.

[0041] Further preferably, the buffer solution in step S4 is added at a material-liquid ratio of 1 g:8 mL.

[0042] Specifically, the temperature of the enzymatic hydrolysis in step S4 is 40-50°C.

[0043] Preferably, the temperature of the enzymatic hydrolysis in step S4 is 40-45°C or 45-50°C.

[0044] More preferably, the temperature of the enzymatic hydrolysis in step S4 is 45°C.

[0045] Specifically, the enzymatic hydrolysis time in step S4 is 100-140 min.

[0046] Preferably, the enzymatic hydrolysis time in step S4 is 100-110 min, 110-120 min, 120-130 min or 130-140 min.

[0047] Further preferably, the enzymatic hydrolysis time in step S4 is 120 min.

[0048] Specifically, the temperature for inactivating the enzyme in step S4 is 80-90°C.

[0049] Preferably, the temperature for inactivating the enzyme in step S4 is 80-85°C or 85-90°C.

[0050] More preferably, the temperature for inactivating the enzyme in step S4 is 85°C.

[0051] Specifically, the time for inactivating the enzyme in step S4 is 5-15 minutes.

[0052] Preferably, the enzyme inactivation time in step S4 is 5-10 min or 10-15 min.

[0053] More preferably, the enzyme inactivation time in step S4 is 10 minutes.

[0054] Specifically, the amount of the acidic protease added in step S5 is 0.75%-1.00% w / w of the mass of the distilled water in step S5.

[0055] Preferably, the amount of the acid protease added in step S5 is 0.75%-0.80% w / w, 0.80%-0.85% w / w, 0.85%-0.90% w / w, 0.90%-0.95% w / w or 0.95%-1.00% w / w of the mass of the distilled water in step S5.

[0056] Further preferably, the amount of the acidic protease added in step S5 is 0.75% w / w or 1.00% w / w of the mass of the distilled water in step S5.

[0057] Still further preferably, the amount of the acid protease added in step S5 is 1.00% w / w of the mass of the distilled water in step S5.

[0058] Specifically, the distilled water described in step S5 is added according to a material-liquid ratio of 1 g: 10-12 mL.

[0059] Preferably, the distilled water in step S5 is added according to a material-liquid ratio of 1 g:10-11 mL or 1 g:11-12 mL.

[0060] Further preferably, the distilled water in step S5 is added according to a material-liquid ratio of 1 g:12 mL.

[0061] Specifically, the pH adjustment in step S5 is to adjust the pH value to 3.0-4.0.

[0062] Preferably, the pH adjustment in step S5 is to adjust the pH value to 3.0-3.1, 3.1-3.2, 3.2-3.3, 3.3-3.4, 3.4-3.5, 3.5-3.6, 3.6-3.7, 3.7-3.8, 3.8-3.9 or 3.9-4.0.

[0063] Further preferably, the pH adjustment in step S5 is to adjust the pH value to 3.5.

[0064] Specifically, the temperature of the enzymatic hydrolysis in step S5 is 50-60°C.

[0065] Preferably, the temperature of the enzymatic hydrolysis in step S5 is 50-55°C or 55-60°C.

[0066] More preferably, the temperature of the enzymatic hydrolysis in step S5 is 55°C.

[0067] Specifically, the enzymatic hydrolysis time in step S5 is 120-180 min.

[0068] Preferably, the enzymatic hydrolysis time in step S5 is 120-130 min, 130-140 min, 140-150 min, 150-160 min, 160-170 min or 170-180 min.

[0069] Further preferably, the enzymatic hydrolysis time in step S5 is 150 min.

[0070] Specifically, the temperature for inactivating the enzyme in step S5 is 85-95°C.

[0071] Preferably, the temperature for inactivating the enzyme in step S5 is 85-90°C or 90-100°C.

[0072] More preferably, the temperature for inactivating the enzyme in step S5 is 90°C.

[0073] Specifically, the time for inactivating the enzyme in step S5 is 5-15 minutes.

[0074] Preferably, the enzyme inactivation time in step S5 is 5-10 min or 10-15 min.

[0075] More preferably, the enzyme inactivation time in step S5 is 10 minutes.

[0076] Specifically, the concentration in step S7 is to concentrate to a relative density of 1.10-1.20 at 60°C.

[0077] Preferably, the concentration in step S7 is concentration to a relative density of 1.10-1.11, 1.11-1.12, 1.12-1.13, 1.13-1.14, 1.14-1.15, 1.15-1.16, 1.16-1.17, 1.17-1.18, 1.18-1.19 or 1.19-1.20 at 60°C.

[0078] Further preferably, the concentration in step S7 is concentration to a relative density of 1.15 at 60°C.

[0079] Specifically, the drying in step S7 includes freeze drying, vacuum drying or spray drying.

[0080] Preferably, the drying in step S7 is spray drying.

[0081] Specifically, the composition is composed of the following raw materials in parts by weight: 1-3 parts of Buza leaves, 1-3 parts of southern hawthorn, 1-3 parts of lotus leaves, 5-10 parts of Pueraria lobata roots, 10-20 parts of Imperata cylindrica roots and 1-3 parts of litchi seeds.

[0082] Preferably, the composition comprises 1-2 parts or 2-3 parts of Buza leaves by weight.

[0083] Further preferably, the composition comprises 1 part, 2 parts or 3 parts of Buza leaves by weight.

[0084] Still further preferably, the composition comprises 2 parts by weight of Buza leaves.

[0085] Preferably, the composition comprises 1-2 parts or 2-3 parts of southern hawthorn by weight.

[0086] Further preferably, the composition comprises 1 part, 2 parts or 3 parts of southern hawthorn by weight.

[0087] Still further preferably, the composition comprises 2 parts of southern hawthorn by weight.

[0088] Preferably, the composition comprises 1-2 parts or 2-3 parts of lotus leaves by weight.

[0089] Further preferably, the composition comprises 1 part, 2 parts or 3 parts of lotus leaves by weight.

[0090] Still further preferably, the composition comprises 2 parts by weight of lotus leaves.

[0091] Preferably, the composition comprises 5-6 parts, 6-7 parts, 7-8 parts, 8-9 parts, or 9-10 parts of Pueraria lobata by weight.

[0092] Further preferably, the composition comprises 5 parts, 8 parts or 10 parts of Pueraria lobata by weight.

[0093] Still further preferably, the composition comprises 5 parts of Pueraria lobata by weight.

[0094] Preferably, the composition comprises 10-11 parts, 11-12 parts, 12-13 parts, 13-14 parts, 14-15 parts, 15-16 parts, 16-17 parts, 17-18 parts, 18-19 parts or 19-20 parts of Imperata rhizome by weight.

[0095] More preferably, the composition comprises 10 parts, 15 parts or 20 parts of Imperata rhizome by weight.

[0096] Still further preferably, the composition comprises 10 parts by weight of Imperata cylindrica rhizome.

[0097] In another aspect, the present invention provides a method for preparing any one of the above compositions.

[0098] In another aspect, the present invention provides use of any of the above compositions in preparing a product, wherein the product comprises any one or more of the following: (1) Health supplements that help control body fat; (2) Drugs that reduce body fat or uric acid.

[0099] In another aspect, the present invention provides a health care product, characterized in that the health care product comprises any one of the above-mentioned compositions.

[0100] Specifically, the dosage form of the health care product includes a solid dosage form, a semisolid dosage form or a liquid dosage form.

[0101] Preferably, the dosage forms of the health care product include but are not limited to tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids or drops.

[0102] Specifically, the health care product also includes nutritional additives that are nutritionally acceptable.

[0103] Preferably, the nutritional additives include, but are not limited to, one or more of dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0104] In another aspect, the present invention provides a medicine comprising any one of the above-mentioned compositions.

[0105] Preferably, the dosage form of the drug includes any one or more of tablets, pills, powders, suspensions, gels, emulsions, creams, granules, capsules, suppositories, injections, sprays, and injections.

[0106] Specifically, the medicine also includes pharmaceutically acceptable excipients.

[0107] Preferably, the pharmaceutically acceptable excipients include: one or a combination of two or more of wetting agents, emulsifiers, preservatives, antioxidants, buffers, diluents, lubricants, solutes, suspending agents, solubilizers, thickeners, stabilizers, sweeteners, and flavors.

[0108] In another aspect, the present invention provides a method for helping to control body fat, wherein the method comprises using any one of the above-mentioned compositions, health products or medicines.

[0109] Specifically, the method comprises administering an effective amount of a composition, health product or medicine to a subject.

[0110] Preferably, the subject is a mammal.

[0111] More preferably, the subject is a human.

[0112] In another aspect, the present invention provides a method for reducing body fat or reducing uric acid, wherein the method comprises using any of the above-mentioned compositions, health products or medicines.

[0113] Specifically, the method comprises administering an effective amount of a composition, health product or medicine to a subject.

[0114] Preferably, the subject is a mammal.

[0115] More preferably, the subject is a human.

[0116] The beneficial effects of the present invention are: The composition of the present invention can be used to prepare health products that help control body fat and drugs that reduce body fat or uric acid. Compared to existing products, the composition of the present invention has an advanced preparation process, can effectively improve the dissolution rate of the active ingredient, has a clear mechanism of action, and uses natural raw materials, which is highly safe. It has significant effects in reducing fat and lowering uric acid, and has important application value and broad market prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0117] Figure 1 The results of uric acid content determination; *** in the figure represents the difference between the blank group and the control group. P <0.001; **** represents compared with the blank group P <0.0001; #### represents compared with the model group P <0.0001; $ represents comparison with positive control group P <0.05; $$ represents comparison with the positive control group P <0.01; $$$$ represents comparison with the positive control group P <0.0001; &&& represents comparison with Example 1 group P <0.001; &&&& represents comparison with Example 1 group P <0.0001.

[0118] Figure 2 The results of the determination of triglyceride and total cholesterol in the blood; * in the figure represents the comparison with the blank control group P <0.05; ** represents comparison with blank control group P <0.01; **** represents compared with the blank control group P <0.0001; #### represents compared with the model control group P <0.0001. DETAILED DESCRIPTION

[0119] The present invention will be further clarified and fully described below by way of examples. The following examples are only a portion of the present invention and are not intended to limit the present invention, but are merely for illustration. The experimental methods used in the following examples are all routine experiments unless otherwise specified, and the materials and reagents used in the following examples are all commercially available unless otherwise specified.

[0120] Example 1 A composition is composed of the following raw materials: 2 parts of Buza leaves, 2 parts of southern hawthorn, 2 parts of lotus leaves, 5 parts of Pueraria root, 10 parts of Imperata root, and 2 parts of litchi seeds. The preparation method of the composition is as follows: 1. Raw material preparation: (1) Grind the Buza leaves and lotus leaves through a 40-mesh sieve, and mix them according to weight to obtain a medicinal material powder 1; (2) Remove the core of southern hawthorn and crush it through a 50-mesh sieve. Crush the litchi core into granules and mix them according to weight to obtain medicinal material powder 2.

[0121] (3) Slice the Pueraria root and Imperata root and set aside.

[0122] 2. Preparation of the composition: S1. Mix kudzu root slices and Imperata cylindrica root slices according to weight, add distilled water at a material-liquid ratio of 1 g:10 mL, stir evenly, add 0.5% w / w sophoroside by weight of distilled water, soak for 60 min, extract at 50°C for 40 min, repeat the extraction and filtration three times, and combine the filtrates to obtain the drug extract and drug residue 1; S2. Combine the medicinal material powder 1 and the medicinal residue 1, add phosphate buffer of pH 5.0 at a material-liquid ratio of 1 g:8 mL, add 1.2% w / w aminopeptidase and 1.0% w / w cellulase by mass of the phosphate buffer, hydrolyze at 45°C for 120 min, inactivate the enzyme at 85°C for 10 min, and filter to obtain the enzymatic hydrolyzate 1 and the medicinal residue 2; S3, combine the medicinal material powder 2 and the medicinal residue 2, add distilled water at a material-liquid ratio of 1 g:12 mL, adjust the pH to 3.5, add 1.0% w / w acid protease by the mass of distilled water, hydrolyze at 55°C for 150 min, inactivate the enzyme at 90°C for 10 min, and filter to obtain the enzymatic hydrolyzate 2; S4, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S5. The enzymatic extract is filtered, and the filtrate is concentrated to a relative density of 1.15 (60° C.), and spray-dried to obtain a composition.

[0123] Example 2 A composition is composed of the following raw materials: 3 parts of Buza leaves, 1 part of southern hawthorn, 1 part of lotus leaves, 8 parts of Pueraria root, 15 parts of Imperata root, and 1 part of litchi seed. The preparation method of the composition is as follows: 1. Raw material preparation: refer to Example 1.

[0124] 2. Preparation of the composition: S1. Mix kudzu root slices and Imperata cylindrica root slices according to weight, add distilled water at a material-liquid ratio of 1 g:15 mL, stir evenly, add 1.0% w / w sophoroside by weight of distilled water, soak for 60 min, extract at 50°C for 40 min, repeat the extraction and filtration three times, and combine the filtrates to obtain the drug extract and drug residue 1; S2. Combine the medicinal material powder 1 and the medicinal residue 1, add phosphate buffer of pH 5.0 at a material-liquid ratio of 1 g:10 mL, add 1.5% w / w aminopeptidase and 1.0% w / w cellulase by mass of the phosphate buffer, hydrolyze at 45°C for 120 min, inactivate the enzyme at 85°C for 10 min, and filter to obtain the enzymatic hydrolyzate 1 and the medicinal residue 2; S3, combine the medicinal material powder 2 and the medicinal residue 2, add distilled water at a material-liquid ratio of 1 g:15 mL, adjust the pH to 3.5, add 0.75% w / w acid protease by the mass of distilled water, hydrolyze at 55°C for 150 min, inactivate the enzyme at 90°C for 10 min, and filter to obtain the enzymatic hydrolyzate 2; S4, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S5. The enzymatic extract is filtered, and the filtrate is concentrated to a relative density of 1.15 (60° C.), and spray-dried to obtain a composition.

[0125] Example 3 A composition comprising the following ingredients: 1 part of Buza leaves, 3 parts of southern hawthorn, 3 parts of lotus leaves, 10 parts of Pueraria root, 20 parts of Imperata root, and 3 parts of litchi seeds. The preparation method of the composition is as follows: 1. Raw material preparation: refer to Example 1.

[0126] 2. Preparation of the composition: S1. Mix kudzu root slices and Imperata cylindrica root slices according to weight, add distilled water at a material-liquid ratio of 1 g:10 mL, stir evenly, add 0.75% w / w sophoroside by weight of distilled water, soak for 60 min, extract at 50°C for 40 min, repeat the extraction and filtration three times, and combine the filtrates to obtain the drug extract and drug residue 1; S2. Combine the medicinal material powder 1 and the medicinal residue 1, add phosphate buffer of pH 5.0 at a material-liquid ratio of 1 g:8 mL, add 1.0% w / w aminopeptidase and 1.0% w / w cellulase by mass of the phosphate buffer, perform enzymatic hydrolysis at 45°C for 120 min, inactivate the enzyme at 85°C for 10 min, and filter to obtain the enzymatic hydrolyzate 1 and the medicinal residue 2; S3, combine the medicinal material powder 2 and the medicinal residue 2, add distilled water at a material-liquid ratio of 1g:10mL, adjust the pH to 3.5, add 1.0% w / w acid protease by the mass of distilled water, hydrolyze at 55°C for 150min, inactivate the enzyme at 90°C for 10min, and filter to obtain the enzymatic hydrolyzate 2; S4, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S5. The enzymatic extract is filtered, and the filtrate is concentrated to a relative density of 1.15 (60° C.), and spray-dried to obtain a composition.

[0127] Comparative Example 1 A composition is composed of the following raw materials: 2 parts of Buza leaves, 2 parts of southern hawthorn, 2 parts of lotus leaves, 15 parts of Imperata roots, and 2 parts of litchi seeds. The preparation method of the composition is as follows: 1. Raw material preparation: (1) Grind the Buza leaves and lotus leaves through a 40-mesh sieve, and mix them according to weight to obtain a medicinal material powder 1; (2) Remove the core of southern hawthorn and crush it through a 50-mesh sieve. Crush the litchi core into granules and mix them according to weight to obtain medicinal material powder 2.

[0128] (3) Slice the Imperata root and set aside.

[0129] 2. Preparation of the composition: S1. Slice the Imperata root, add distilled water at a material-liquid ratio of 1 g:10 mL, stir evenly, add 0.5% w / w sophoroside by weight of distilled water, soak for 60 min, extract at 50°C for 40 min, repeat the extraction and filtration three times, combine the filtrates to obtain the drug extract and drug residue 1; S2. Combine the medicinal material powder 1 and the medicinal residue 1, add phosphate buffer of pH 5.0 at a material-liquid ratio of 1 g:8 mL, add 1.2% w / w aminopeptidase and 1.0% w / w cellulase by mass of the phosphate buffer, hydrolyze at 45°C for 120 min, inactivate the enzyme at 85°C for 10 min, and filter to obtain the enzymatic hydrolyzate 1 and the medicinal residue 2; S3, combine the medicinal material powder 2 and the medicinal residue 2, add distilled water at a material-liquid ratio of 1 g:12 mL, adjust the pH to 3.5, add 1.0% w / w acid protease by the mass of distilled water, hydrolyze at 55°C for 150 min, inactivate the enzyme at 90°C for 10 min, and filter to obtain the enzymatic hydrolyzate 2; S4, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S5. The enzymatic extract is filtered, and the filtrate is concentrated to a relative density of 1.15 (60° C.), and spray-dried to obtain a composition.

[0130] Comparative Example 2 A composition is composed of the following raw materials: 4 parts of Buza leaves, 4 parts of Crataegus pinnatifida, 5 parts of Pueraria lobata roots, and 10 parts of Imperata cylindrica roots. The preparation method of the composition is as follows: 1. Raw material preparation: (1) Grind the leaves of Buza and pass them through a 40-mesh sieve to obtain medicinal material powder 1; (2) Remove the core of southern hawthorn and crush it through a 50-mesh sieve to obtain medicinal powder 2.

[0131] (3) Slice the Pueraria root and Imperata root and set aside.

[0132] 2. Preparation of the composition: S1. Mix kudzu root slices and Imperata cylindrica root slices according to weight, add distilled water at a material-liquid ratio of 1 g:10 mL, stir evenly, add 0.5% w / w sophoroside by weight of distilled water, soak for 60 min, extract at 50°C for 40 min, repeat the extraction and filtration three times, and combine the filtrates to obtain the drug extract and drug residue 1; S2. Combine the medicinal material powder 1 and the medicinal residue 1, add phosphate buffer of pH 5.0 at a material-liquid ratio of 1 g:8 mL, add 1.2% w / w aminopeptidase and 1.0% w / w cellulase by mass of the phosphate buffer, hydrolyze at 45°C for 120 min, inactivate the enzyme at 85°C for 10 min, and filter to obtain the enzymatic hydrolyzate 1 and the medicinal residue 2; S3, combine the medicinal material powder 2 and the medicinal residue 2, add distilled water at a material-liquid ratio of 1 g:12 mL, adjust the pH to 3.5, add 1.0% w / w acid protease by the mass of distilled water, hydrolyze at 55°C for 150 min, inactivate the enzyme at 90°C for 10 min, and filter to obtain the enzymatic hydrolyzate 2; S4, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S5. The enzymatic extract is filtered, and the filtrate is concentrated to a relative density of 1.15 (60° C.), and spray-dried to obtain a composition.

[0133] Comparative Example 3 A composition is composed of the following raw materials: 4 parts of Buza leaves, 4 parts of southern hawthorn, and 15 parts of Imperata rhizome. The preparation method of the composition is as follows: 1. Raw material preparation: (1) Grind the leaves of Buza and pass them through a 40-mesh sieve to obtain medicinal material powder 1; (2) Remove the core of southern hawthorn and crush it through a 50-mesh sieve to obtain medicinal powder 2.

[0134] (3) Slice the Imperata root and set aside.

[0135] 2. Preparation of the composition: S1. Slice the Imperata root, add distilled water at a material-liquid ratio of 1 g:10 mL, stir evenly, add 0.5% w / w sophoroside by weight of distilled water, soak for 60 min, extract at 50°C for 40 min, repeat the extraction and filtration three times, combine the filtrates to obtain the drug extract and drug residue 1; S2. Combine the medicinal material powder 1 and the medicinal residue 1, add phosphate buffer of pH 5.0 at a material-liquid ratio of 1 g:8 mL, add 1.2% w / w aminopeptidase and 1.0% w / w cellulase by mass of the phosphate buffer, hydrolyze at 45°C for 120 min, inactivate the enzyme at 85°C for 10 min, and filter to obtain the enzymatic hydrolyzate 1 and the medicinal residue 2; S3, combine the medicinal material powder 2 and the medicinal residue 2, add distilled water at a material-liquid ratio of 1 g:12 mL, adjust the pH to 3.5, add 1.0% w / w acid protease by the mass of distilled water, hydrolyze at 55°C for 150 min, inactivate the enzyme at 90°C for 10 min, and filter to obtain the enzymatic hydrolyzate 2; S4, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S5. The enzymatic extract is filtered, and the filtrate is concentrated to a relative density of 1.15 (60° C.), and spray-dried to obtain a composition.

[0136] Comparative Example 4 A composition is composed of the following ingredients: 2 parts of Panax notoginseng leaves, 2 parts of southern hawthorn, 2 parts of lotus leaves, 5 parts of Pueraria lobata roots, 10 parts of burdock roots, and 2 parts of longan seeds. The preparation method of the composition is as follows: 1. Raw material preparation: (1) Grind the Panax notoginseng leaves and lotus leaves through a 40-mesh sieve, and mix them according to weight to obtain medicinal material powder 1; (2) Remove the core of southern hawthorn and crush it through a 50-mesh sieve. Crush the longan core into granules and mix them according to weight to obtain medicinal material powder 2.

[0137] (3) Slice the kudzu root and burdock root and set aside.

[0138] 2. Preparation of the composition: S1. Slices of Pueraria lobata and burdock root were mixed according to weight, and distilled water was added at a material-liquid ratio of 1 g:10 mL. After stirring evenly, 0.5% w / w sophoroside by weight of distilled water was added, and the mixture was soaked for 60 min, extracted at 50° C. for 40 min, and the extraction and filtration were repeated 3 times. The filtrates were combined to obtain a drug extract and a drug residue 1. S2. Combine the medicinal material powder 1 and the medicinal residue 1, add phosphate buffer of pH 5.0 at a material-liquid ratio of 1 g:8 mL, add 1.2% w / w aminopeptidase and 1.0% w / w cellulase by mass of the phosphate buffer, hydrolyze at 45°C for 120 min, inactivate the enzyme at 85°C for 10 min, and filter to obtain the enzymatic hydrolyzate 1 and the medicinal residue 2; S3, combine the medicinal material powder 2 and the medicinal residue 2, add distilled water at a material-liquid ratio of 1 g:12 mL, adjust the pH to 3.5, add 1.0% w / w acid protease by the mass of distilled water, hydrolyze at 55°C for 150 min, inactivate the enzyme at 90°C for 10 min, and filter to obtain the enzymatic hydrolyzate 2; S4, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S5. The enzymatic extract is filtered, and the filtrate is concentrated to a relative density of 1.15 (60° C.), and spray-dried to obtain a composition.

[0139] Comparative Example 5 A composition is composed of the following raw materials: 2 parts of Buza leaves, 2 parts of southern hawthorn, 2 parts of lotus leaves, 5 parts of Pueraria root, 10 parts of Imperata root, and 2 parts of litchi seeds. The preparation method of the composition is as follows: 1. Raw material preparation: refer to Example 1.

[0140] 2. Preparation of the composition: S1. Mix kudzu root slices and Imperata cylindrica root slices according to weight, add distilled water at a material-liquid ratio of 1 g:10 mL, stir evenly, add 0.5% w / w rhamnolipid by weight of distilled water, soak for 60 min, extract at 50°C for 40 min, repeat the extraction and filtration three times, combine the filtrates to obtain the drug extract and drug residue 1; S2. Combine the medicinal material powder 1 and the medicinal residue 1, add phosphate buffer of pH 5.0 at a material-liquid ratio of 1 g:8 mL, add 2.2% w / w cellulase by weight of the phosphate buffer, perform enzymatic hydrolysis at 45°C for 120 min, inactivate the enzyme at 85°C for 10 min, and filter to obtain the enzymatic hydrolyzate 1 and the medicinal residue 2; S3, combine the medicinal material powder 2 and the medicinal residue 2, add distilled water at a material-liquid ratio of 1 g:12 mL, adjust the pH to 3.5, add 1.0% w / w acid protease by the mass of distilled water, hydrolyze at 55°C for 150 min, inactivate the enzyme at 90°C for 10 min, and filter to obtain the enzymatic hydrolyzate 2; S4, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S5. The enzymatic extract is filtered, and the filtrate is concentrated to a relative density of 1.15 (60° C.), and spray-dried to obtain a composition.

[0141] Comparative Example 6 A composition is composed of the following raw materials: 2 parts of Buza leaves, 2 parts of southern hawthorn, 2 parts of lotus leaves, 5 parts of Pueraria root, 10 parts of Imperata root, and 2 parts of litchi seeds. The preparation method of the composition is as follows: 1. Raw material preparation: refer to Example 1.

[0142] 2. Preparation of the composition: S1. Mix kudzu root slices and Imperata cylindrica root slices according to weight, add distilled water at a material-liquid ratio of 1 g:10 mL, stir evenly, add 0.5% w / w sophoroside by weight of distilled water, soak for 60 min, extract at 50°C for 40 min, repeat the extraction and filtration three times, and combine the filtrates to obtain the drug extract and drug residue 1; S2. Combine medicinal material powder 1, medicinal material powder 2, and medicinal residue 1, add phosphate buffer at pH 5.0 at a material-liquid ratio of 1 g:12 mL, add 1.2% w / w aminopeptidase, 1.0% w / w cellulase, and 1.0% w / w acid protease by mass of phosphate buffer, and hydrolyze at 55°C for 270 min, inactivate the enzyme at 90°C for 10 min, and filter to obtain the enzymatic solution; S3, mixing the drug extract and the enzymatic hydrolysis solution to obtain an enzymatic hydrolysis extract; S4. The enzymatic extract is filtered, and the filtrate is concentrated to a relative density of 1.15 (60° C.), and spray-dried to obtain a composition.

[0143] Experimental Example 1 Uric acid-lowering effect of the composition HK-2 cells in logarithmic growth phase were cultured at 2×10 5 Cells were seeded into 6-well plates and cultured in complete medium for 24 h. After the cells adhered, the culture medium was aspirated and the cells were washed three times with PBS. The following grouping and dosing were performed: Blank group: cultured in complete medium for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium for another 24 h; Modeling group: cultured in complete medium for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 h; Positive control group: cultured in complete medium containing 0.1 mmol / L febuxostat for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 h; Example 1 group: cultured in complete medium containing 500 μg / mL of the composition of Example 1 for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 h; Example 2 group: cultured in complete medium containing 500 μg / mL of the composition of Example 2 for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 h; Example 3 group: cultured in complete medium containing 500 μg / mL of the composition of Example 3 for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 h; Comparative Example 1 group: The cells were cultured in a complete medium containing 500 μg / mL of the composition of Comparative Example 1 for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in a serum-free medium containing 0.5 mmol / L adenosine for 24 h; Comparative Example 2 group: The cells were cultured in a complete medium containing 500 μg / mL of the composition of Comparative Example 2 for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in a serum-free medium containing 0.5 mmol / L adenosine for 24 h; Comparative Example 3 group: cultured in complete medium containing 500 μg / mL of the composition of Comparative Example 3 for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 h; Comparative Example 4 group: cultured in complete medium containing 500 μg / mL of the composition of Comparative Example 4 for 24 hours, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 hours; Comparative Example 5 group: cultured in complete medium containing 500 μg / mL of the composition of Comparative Example 5 for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 h; Comparative Example 6 group: The cells were cultured in complete medium containing 500 μg / mL of the composition of Comparative Example 6 for 24 h, the culture medium was aspirated and washed three times with PBS, and then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 h.

[0144] After the above grouping treatments were completed, 0.005 U / mL xanthine oxidase was added to each group and cultured for 1 hour. The cell supernatant was collected and the uric acid content was determined according to the kit instructions. If the uric acid content in the cell supernatant of the model group was significantly higher than that of the blank control group ( P <0.0001), the final uric acid production in the positive control group was significantly lower than that in the model group ( P <0.0001), and showed a certain concentration-dose effect, indicating that the model was basically successfully constructed. The measurement results are shown in Table 1 and Figure 1 shown.

[0145] Table 1

[0146] The results of uric acid determination showed that the compositions of Examples 1 to 3 and Comparative Examples 1 to 6 were able to significantly reduce the uric acid content in the model group. The uric acid-lowering effects of Examples 1 to 3 were better than those of the positive control group, among which the uric acid-lowering effect of Example 1 was the best ( P <0.0001).

[0147] Experimental Example 2 Fat-reducing effect of the composition A total of 30 5-week-old C57BL / 6J male mice were randomly divided into a blank control group and an experimental group after 7 days of adaptive feeding. The mice in the blank control group were fed with mouse maintenance feed daily, and the mice in the experimental group were fed with mouse high-fat feed daily. After 12 weeks, the weight of the mice in the blank control group was weighed and the average was taken, and the weight of the mice in the experimental group was weighed. If the weight of the mice in the experimental group was ≥120% of the average weight of the mice in the blank control group, the model was judged to be successful. The mice in the experimental group were randomly divided into a model group and Example 1 group to Example 3 group, with 6 mice in each group. Different intervention methods were performed on mice in different groups after grouping: The blank control group continued to be fed with the mouse maintenance feed; the model control group continued to be fed with the high-fat feed; the Example 1-Example 3 groups continued to be fed with the high-fat feed and were gavaged daily with 500 mg / kg of the composition of Example 1-Example 3. After 6 weeks of intervention, the body weight of each group of mice and the levels of triglyceride (TG) and total cholesterol (TC) in their blood were measured. The results are shown in Table 2 and Figure 2 shown.

[0148] Table 2

[0149] The test results showed that the compositions of Examples 1 to 3 of the present invention could significantly reduce the TG and TC levels in the blood of the mice in the model control group ( P <0.0001). The compositions of Examples 1 to 3 were able to restore the TG content to normal levels, with no significant difference compared to the blank control group; the composition of Example 1 was able to restore the TC content to normal levels, with no significant difference compared to the blank control group.

[0150] The above detailed description is a specific description of one feasible embodiment of the present invention and is not intended to limit the scope of the present invention. It should be noted that any equivalent implementation or modification that does not depart from the present invention should be included within the scope of the technical solution of the present invention. Therefore, the scope of protection of the patent of this invention should be based on the attached requirements.

Claims

1. A composition for reducing fat and lowering uric acid, characterized in that: The composition is composed of the following raw materials Ingredients: Buza leaves, southern hawthorn, lotus leaves, wild kudzu root, white cypress root and litchi seeds; The preparation method of the composition is as follows: S1. Grind and sieve the Buza leaves and lotus leaves, and then mix them to obtain medicinal material powder 1; S2, remove the core of southern hawthorn, crush and sieve, crush the litchi core into granules, and mix them to obtain medicinal material powder 2; S3, slicing Pueraria lobata and Imperata cylindrica root, mixing them, adding distilled water, stirring evenly, adding sophoroside, soaking, repeating extraction and filtration 3 times, combining the filtrate to obtain the drug extract and the residue 1; S4, combining the medicinal material powder 1 and the medicinal residue 1, adding a buffer solution, adding aminopeptidase and cellulase, performing enzymolysis, inactivating the enzymes, and filtering to obtain an enzymatic hydrolyzate 1 and the medicinal residue 2; S5, combining the medicinal material powder 2 and the medicinal residue 2, adding distilled water, adjusting the pH, adding acidic protease, performing enzymatic hydrolysis, inactivating the enzyme, and filtering to obtain an enzymatic hydrolyzate 2; S6, mixing the drug extract, enzymatic hydrolyzate 1 and enzymatic hydrolyzate 2 to obtain an enzymatic hydrolyzed extract; S7. Filter the enzymatic extract, concentrate and dry to obtain the composition.

2. The composition according to claim 1, characterized in that The amount of the sophoroside added in step S3 is 0.5%-1.0% w / w of the mass of the distilled water described in step S3; the amount of the aminopeptidase added in step S4 is 1.0%-1.5% w / w of the mass of the buffer described in step S4; the amount of the cellulase added in step S4 is 1.0% w / w of the mass of the buffer described in step S4; and the amount of the acid protease added in step S5 is 0.75%-1.0% w / w of the mass of the distilled water described in step S5.

3. The composition according to claim 1, characterized in that The amount of the sophoroside added in step S3 is 1.0% w / w of the mass of the distilled water described in step S3; the amount of the aminopeptidase added in step S4 is 1.0%-1.2% w / w of the mass of the buffer described in step S4; the amount of the cellulase added in step S4 is 1.0% w / w of the mass of the buffer described in step S4; and the amount of the acid protease added in step S5 is 1.0% w / w of the mass of the distilled water described in step S5.

4. The composition according to claim 1, characterized in that The distilled water described in step S3 is added according to the material-liquid ratio of 1g:10-15mL; The buffer solution described in step S4 is added at a material-liquid ratio of 1 g: 8-10 mL; The distilled water described in step S5 is added according to a material-liquid ratio of 1 g: 10-12 mL.

5. The composition according to claim 1, characterized in that The composition is composed of the following raw materials in parts by weight: 1-3 parts of Buza leaves, 1-3 parts of southern hawthorns, 1-3 parts of lotus leaves, 5-10 parts of Pueraria lobata roots, 10-20 parts of Imperata cylindrica roots and 1-3 parts of litchi seeds.

6. The composition according to claim 1, characterized in that The composition comprises the following raw materials in parts by weight: Ingredients: 2 parts of Buza leaves, 2 parts of southern hawthorn, 2 parts of lotus leaves, 5 parts of wild kudzu roots, 10 parts of white imperata roots and 2 parts of litchi seeds.

7. A method for preparing the composition according to any one of claims 1 to 6.

8. Use of the composition according to any one of claims 1 to 6 in preparing a product, characterized in that: The products include any one or more of the following: (1) Health supplements that help control body fat; (2) Drugs that reduce body fat or uric acid.

9. A health care product, characterized in that: The health care product comprises the composition according to any one of claims 1 to 6.

10. A medicine, characterized in that: The medicine comprises the composition according to any one of claims 1 to 6.

Images